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Abstract Recently, the first genome-wide association
(GWA) study in frontotemporal lobar degeneration (FTLD)
identified common genetic variability at the TMEM106B
gene on chromosome 7p21.3 as a potential important risk-
modifying factor for FTLD with pathologic inclusions of
TAR DNA-binding protein (FTLD-TDP), the most com-
mon pathological subtype in FTLD. To gather additional
evidence for the implication of TMEM106B in FTLD risk,
multiple replication studies in geographically distinct
populations were set up. In this review, we revise all recent
replication and follow-up studies of the FTLD-TDP GWA
study and summarize the growing body of evidence that
establish TMEM106B as a bona fide risk factor for FTLD.
With the TMEM106B gene, a new player has been
identified in the pathogenic cascade of FTLD which could
hold important implications for the future development of
disease-modifying therapies.
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In an attempt to resolve the missing heritability in neurodegen-
erative diseases, genetic research has shifted focus from linkage
and positional cloning studies in multigenerational families for
the identification of rare causal genes, towards genome-wide
association (GWA) studies for the identification of more
common genetic risk factors. In ever-growing sample sizes,
these studies have become increasingly successful, e.g., in
amyotrophic lateral sclerosis (ALS, (van Es et al. 2009)),
Parkinson's disease (Simon-Sanchez et al. 2009), and Alz-
heimer's disease (Lambert et al. 2009; Harold et al. 2009).
However, in FTLD research, likely due to the higher familial
load in this dementia subtype (up to 30–40% of patients have
a positive family history), the first GWA study was only
recently undertaken. In FTLD, the known causal genes
explain 10% to 20% of all patients. In our Flanders–Belgian
FTLD cohort (n=315) for example, we have observed 35
patients with a mutation in GRN (n=13), MAPT (n=4), VCP
(n=2), CHMP2B (n=1), FUS (n=1), or PSEN1 (n=1)
representing 11% of the total population and 29% of familial
patients. Notwithstanding, a significant fraction of patients,
including the familial patients, remains unresolved. In the
beginning of 2010, the results of the first GWA study in
FTLD were published (Van Deerlin et al. 2010). Although
there had been skepticism about the success of such a GWA
study in FTLD, because of its inherent clinical and pathologic
heterogeneity, this study ensured its success by including only
patients with FTLD-TDP pathology. Despite having to pay a
penalty for more limited sample size, this approach dramat-
ically reduced the genetic heterogeneity of their study
population and thereby their power to identify disease
association. In an international collaboration including 45
sites from 11 countries, DNA from 515 patients with
confirmed FTLD-TDP pathology, either by histopathology
or presence of a GRN mutation, was collected. Comparison
of the FTLD-TDP patients to 2,509 control individuals
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identified three single-nucleotide polymorphisms (SNPs)
with genome-wide significance (rs1020004, rs6966915, and
rs1990622). The three top SNPs mapped to a single linkage
disequilibrium (LD)-block of 68 kb at 7p21.3 encompassing
the gene coding for TMEM106B, an uncharacterized
transmembrane protein, and two other genes at the rim of
the associated region, scinderin (SCIN) and ADP-
ribosylation factor-like 4A (ARL4A) (Van Deerlin et al.
2010). The association was strongest in carriers of patho-
genic GRN mutations, suggesting a disease modifying effect
of TMEM106B SNPs in GRN mutation carriers. Moreover,
expression studies in brain demonstrated that TMEM106B is
expressed in frontal cortex (heavily affected in FTLD) and is
significantly increased in FTLD-TDP patients compared to
unaffected individuals, providing initial biological evidence
for TMEM106B as a novel risk factor for FTLD-TDP.
When establishing new risk genes identified through GWA
studies of complex diseases, replications in independent study
populations are paramount. Hereto, we set out to replicate the
association of FTLDwith the TMEM106B locus in a Flanders–
Belgian patient-control cohort (van der Zee et al. 2011).
Whereas the original study purposely selected patients with
FTLD-TDP pathology, we investigated a cohort of patients
with primarily clinical diagnoses of FTLD, in the absence of
postmortem histopathology. One might argue that this
inclusion criterion would result in a too heterogeneous patient
cohort. We addressed this concern by reducing as much as
possible the fraction of FTLD-tau in our sample. Patients of
whom histopathology was available and was indicative of
non-TDP pathology, such as FTLD-tau or FTLD-FUS, were
excluded. Furthermore, patients with non-TDP associated
mutations, such as MAPT, CHMP2B, or PSEN1 mutations,
were excluded. Also, limiting inclusion to patients with a
clinical diagnosis of the three major FTLD subtypes FTD,
PNFA, and SD, but not of CBS or PSP further reduced the
presence of FTLD-tau in our patient cohort. Finally, replica-
tion in a Flanders–Belgian population has the added advan-
tage that patients and control individuals originate from a
small geographical region and have shown limited geographic
mobility over time, in turn reducing the genetic heterogeneity
as exemplified by recurrence of Flanders–Belgian founder
mutations (Cruts et al. 2006; Nuytemans et al. 2008). In 288
patients who were not previously included in the GWA study
and 595 unaffected patients, we replicated association of
FTLD with the three 7p21.3 top SNPs (van der Zee et al.
2011). Allelic association reached significant p values of p=
0.008, p=0.013, and p=0.041 for rs1990622, rs6966915,
and rs1020004, respectively (Table 1). For SNP rs1990622
showing the strongest evidence of association, the odds ratio
(OR) for the minor allele was 0.75 [95% confidence interval
(CI) 0.61–0.93]. Comparing genotype frequencies and
associated effect sizes, a minimal OR was calculated for
rs1020004 (ORCC=0.51, [95% CI 0.29–0.91], p=0.023)
(Table 2). For rs1990622, one copy of the risk allele was
sufficient to achieve a significantly decreased risk effect
(ORCT=0.72, [95% CI 0.53–0.98], p=0.036; ORCC=0.59,
[95% CI 0.38–0.91], p=0.019) (Table 2). In other words,
carriers of one or two copies of the TMEM106B protective
alleles, have a 30% to 50% reduced risk of developing
FTLD. To screen for potential functional variants and to
investigate whether TMEM106B could not only be a risk
factor but also a causative gene for FTLD, we performed
exon sequencing analysis of TMEM106B in the population
of Flanders–Belgian FTLD patients. Of the 61 detected
sequence variants, merely 2 predicted amino acid substitu-
tions, S134N and T185S (Fig. 1). S134N is located in exon 5
and was detected with equal frequency of 2% in patients as
in control individuals. T185S (rs3173615), located in exon 6,
was observed with a frequency of 35% in patients versus
42% in control individuals. Of the remainder of the SNPs,
none were predicted to be near splice sites, transcription
factor binding sites, or microRNA binding sites, indicating
that TMEM106B does not seem to bear highly penetrant
mutations leading to FTLD in our patient sample. SNP
saturation of the TMEM106B genomic region indicated that
the association is likely restricted to a 36 kb genomic region
containing only the TMEM106B gene (van der Zee et al.
2011). However, fine mapping did not identify additional
independent associated SNPs, other than rs1990622 and
rs1020004. Importantly, rs1990622 and rs1020004, for
Table 1 Allelic association of TMEM106B in the Flanders–Belgian clinical FTLD cohort
dbSNP ID Minor allele Minor allele frequency HWE OR [95% CI] P value
Patients (n=288) Controls (n=595)
rs1020004 C 0.26 0.31 0.44 0.79 [0.63–0.99] 0.041
rs6966915 T 0.35 0.42 1.00 0.77 [0.62–0.95] 0.013
rs1990622 C 0.35 0.42 1.00 0.75 [0.61–0.93] 0.008
SNPs are listed according to their genomic order on chromosome 7. P values and odds ratios (OR) with associated 95% confidence intervals (CI)
were calculated under an additive model using logistic regression adjusted for age and gender. HWE—P value for the test of Hardy–Weinberg
equilibrium in control individuals
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which the correlation (r2) was 0.79 in the Flanders–Belgian
population, were in high LD with 30 more SNPs, including
rs6966915 (third GWA top SNP, r2=0.97 with rs1990622)
and rs3173615 (r2=0.98 with rs1990622) coding for the
missense mutation T185S that we previously identified in
the sequencing analysis. The functional relevance of these
SNPs to FTLD remains unknown at the present. However,
the fact that they are all located in or very close to
TMEM106B, and that no other genes are present in or near
the associated region, makes TMEM106B the most likely
candidate underlying FTLD susceptibility. In silico predic-
tion of the functional properties of the 32 SNPs anticipated
the highest impact for rs3173615, T185S, though the
predicted effect on protein function was modest. The
missense mutation is positioned at codon 185, C-terminal
of the transmembrane domain (codon 97–117). Except for
being a single-pass transmembrane protein, little is currently
known about the function of TMEM106B, making it
difficult to estimate the potential impact of amino acid
substitutions on its biological function. Analysis of protein
conservation, however, indicated that the T-residue at
position 185 is highly conserved among vertebrates.
In addition to the Flanders–Belgian replication study,
other replication studies of TMEM106B are being reported
in geographically distinct populations. Whereas our case–
control study only included ten unrelated patients with a
GRN mutation, Finch and colleagues (2011) focused on the
risk-modifying effect of TMEM106B on GRN-related
FTLD. In contrast to our findings, in 482 clinical FTLD
patients without GRN mutations compared to 822 control
individuals, no association with the TMEM106B SNPs was
observed. However, in a relatively small sample of 78
GRN-positive patients, the TMEM106B variants appeared to
be highly significantly associated, with homozygotes of the
minor alleles decreased to 3% of patients versus 19% of
controls (p=0.009) (Finch et al. 2011). Finch et al. (2011)
attributed this to a protective effect of the TMEM106B
SNPs specific to GRN mutation carriers. We observed a
similar trend in the subset of 97 familial Flemish patients
(counting only ten GRN mutation carriers). Here, homo-
zygotes of the rs1990622 protective C allele were decreased
to 8% (n=7) in patients (compared to 13% in the total
patient population) versus 18% in controls, with a reduced
disease risk of 68% (ORCC=0.32, [95% CI 0.14–0.73], p=
0.007). As both in the original GWA study by Van Deerlin
et al. and the replication study by Finch et al., the effect was
clearly most pronounced in GRN mutation carriers; it is
likely that the TMEM106B protective effect is strong in
GRN-related FTLD. However, our data seem to indicate
that although the effect is clearly present in the GRN-positive
Table 2 Genotypic association of TMEM106B in the Flanders–Belgian clinical FTLD cohort
dbSNP ID Genotype Genotype frequency OR [95% CI] P value
Patients (n=288) Controls (n=595)
rs1020004 TT 0.52 0.48 / /
CT 0.41 0.42 0.91 [0.68–1.23] 0.536
CC 0.06 0.10 0.51 [0.29–0.91] 0.023
rs6966915 CC 0.42 0.34 / /
CT 0.45 0.49 0.74 [0.54–1.01] 0.055
TT 0.13 0.17 0.60 [0.39–0.94] 0.025
rs1990622 TT 0.42 0.33 / /
CT 0.45 0.49 0.72 [0.53–0.98] 0.036
CC 0.13 0.18 0.59 [0.38–0.91] 0.019
P values and odds ratios (OR) with associated 95% confidence intervals (CI) were calculated under an additive model using logistic regression
adjusted for age and gender using the common genotype as reference
Fig. 1 Gene structure of the TMEM106B gene. The relative position
of the three replicated SNPs from the FTLD-TDP GWA study is
indicated. Mutation analysis by exonic sequencing in 288 Flanders–
Belgian FTLD patients identified two coding variants, one rare
missense variant S134N in exon 5 and one common missense variant
T185S (rs3173615) in exon 6. T185S was found in high linkage
disequilibrium with rs1990622 in the Flanders–Belgian population
(r2=98)
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patients, it is not limited to GRN-related FTLD. The higher
genetic load in familial patients is probably at the basis of the
observed stronger genetic association. Although we have to
be mindful of over-stratifying the cohorts in, e.g., subsets of
familial patients or of GRN-positive patients, as this may
result in small, statistically less reliable sample sizes in
which the allele frequencies may be skewed.
In a first step to find biological evidence for the association
of TMEM106B and FTLD-TDP, Van Deerlin et al. (2010)
were able to demonstrate an up to 2.5 increase of
TMEM106B expression in brain frontal cortex of FTLD-
TDP patients compared to controls. This led them to suggest
that TMEM106B confers FTLD-TDP risk by increased
expression. Obtaining high-quality RNA from a significant
number of brain samples is challenging. In our study, we
were able to analyze brain frontal cortex samples from 11
FTLD-TDP patients and 12 control individuals. In this
sample set, we observed no increased TMEM106B expression
in FTLD-TDP patients compared to controls. Although our
number of brain samples was limited, it was in the same
range of the original study (n=25) (van der Zee et al. 2011).
Furthermore, in brain frontal cortex cDNA of 40 unaffected
controls, Cruchaga et al. (2011) also failed to find evidence of
correlation between TMEM106B expression and genotype.
Expression analyses of larger number of patient and control
brains will be vital to resolve whether or not TMEM106B
pathogenesis is mediated by variable gene expression.
Ever since the identification of GRN as a major disease
gene in FTLD, researchers have speculated about the
biological basis of the observed variability in onset age
associated with GRN mutations. GRN mutations lead to
FTLD through haploinsufficiency; still, onset age is highly
variable within and between families and ranges from mid-
forties to mid-seventies (Cruts and Van Broeckhoven 2008).
Furthermore, mutation carriers who died without symptoms
in their 80s have been reported. This strongly suggests that
other genes and/or environmental factors affect onset age in
GRN-related FTLD. Moreover, identification of such genetic
modifiers may expose valuable molecular targets for disease-
modifying therapies. It is in this light that Cruchaga and
colleagues (2011) hypothesized that TMEM106B variants
might explain (part of) this phenotypic variability. They
analyzed 27 symptomatic and 23 presymptomatic GRN
mutation carriers from four previously reported GRN-loss
of function (LOF) families (HDDD1 - Ala237fs, FD1 -
Ala237fs, HDDD2 - Ala9Asp, and the Karolinska family -
Gly35fs) and observed a strong association between
rs1990622 and disease onset, with a mean decrease in onset
age of 13 years for patients homozygote for the risk allele
(T) compared to patients with one or two copies of the minor
protective allele (C) (Cruchaga et al. 2011). Moreover, they
additionally demonstrated a correlation between rs1990622
and GRN plasma levels in 73 healthy individuals (Cruchaga
et al. 2011). In a much more extended control series, Finch
and coworkers (2011) also considered if associated
TMEM106B variants modified disease penetrance in GRN-
positive FTLD by modulating GRN protein levels. In 1,013
plasma samples from healthy controls, they showed that the
TMEM106B SNPS are associated with a modest but
significant increase in GRN protein levels. The findings on
onset age by Cruchaga et al. were not in line with what we
observed in the extended Flanders–Belgian FTLD founder
pedigree segregating the GRN IVS1+5G>C splice donor site
mutation (Cruts et al. 2006; van der Zee et al. 2011). The
founder pedigree consists of 226 clinically well-documented
individuals, who are related in at least seven generations,
including 41 patients and at least 37 asymptomatic at risk
mutation carriers. Onset age among patients ranges from 45
to 76 years, and at least 7 mutation carriers were still free of
symptoms while older than the mean onset age in the
pedigree, including an obligate mutation carrier who died at
81 years of age (Cruts et al. 2006; Brouwers et al. 2007).
Onset age analysis in this powerful multigeneration pedigree
demonstrated no correlation of the TMEM160B variants
rs1040002 and rs1990622 with onset age, failing to explain
the >30 years onset age range in the GRN IVS1+5 G>C
carriers (van der Zee et al. 2011). Therefore, in the Flanders–
Belgian GRN founder family, we see no evidence for a
disease-modifying effect of TMEM106B. Possibly multiple
GRN-LOF modifiers exist and another modifying factor is
contributing to the phenotype in our founder family
compared to the other GRN-LOF families. Although the
control studies by Finch and Cruchaga seem to indicate that
TMEM106B variants influence GRN protein levels and
thereby disease penetrance in GRN-related FTLD, a direct
correlation between GRN plasma levels and onset age has
not been demonstrated to date. Also, the observed increase in
GRN protein levels in healthy homozygous carriers of the
protective TMEM106B alleles seems very limited to be able
to rescue the extreme drop in GRN levels that is observed in
GRN-LOF patients (Ghidoni et al. 2008; Finch et al. 2009;
Sleegers et al. 2009; Sleegers et al. 2010). Further more
elaborate studies in affected versus unaffected GRN-LOF
mutation carriers will be required to gather conclusive
evidence for whether or not TMEM106B is able to modify
disease penetrance and onset age in GRN mutation carriers
by modulating GRN plasma levels.
In a follow-up study by the principal authors of the
FTLD-TDP GWA study, Vass et al. (2010) investigated
whether the FTLD-TDP associated TMEM106B risk geno-
types could also contribute to the risk and disease
presentation of ALS. Although they could not demonstrate
association between the TMEM106B genotypes and ALS,
the protective allele of rs1990622 did appear to be
associated with preserved cognition in ALS patients.
Correlation with cognitive performance was strong as
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measured by the phonemic verbal fluency test, but could
however not be confirmed by other cognitive tests. Their
findings, although preliminary, are of interest in light of
the TDP-43 proteinopathy spectrum that binds FTLD and
ALS. It appears that TMEM106B, as a risk factor for
FTLD, is also able to influence cognitive impairment in
ALS patients. Along this line, Rollinson et al. (2011) set
out to replicate not only the genome-wide associated
TMEM106B locus at 7p21.3 but also investigated the other
suggestive loci identified by the FTLD-TDP GWAS on
chromosomes 1, 8, 9, 10, and 11 that reached sub-
threshold significance. In a clinical cohort of 470 British
patients, replication at chromosomes 1, 7, 8, 9, 10, and 11
was negative. However, when restricting the analysis to
the 84 patients with an FTLD-ALS phenotype, convincing
evidence for association was found at multiple SNPs on
the 9p locus, a locus well known to be linked to multiple
FTLD-ALS families (ALSFTD2, (Boxer et al. 2011;
Gijselinck et al. 2010; Le Ber et al. 2009; Luty et al.
2008; Valdmanis et al. 2008; Morita et al. 2006; Vance et
al. 2006)) as well as being associated to ALS risk (van Es
et al. 2009). This study again suggests that FTLD and ALS
share a common genetic basis that also includes shared
genetic risk factors.
In conclusion, although the multiple replication and
follow-up studies differed somewhat in research focus
and therefore resulting observations, overall, the findings
from the different research groups in geographically
distinct populations seem to point out TMEM106B as
bona fide risk factor for FTLD. Further research is needed
to learn whether T185S, variable gene expression or
another mechanism contributes to the disease biology
driving the association of TMEM106B with FTLD. Hereto,
targeted resequencing of the TMEM106B genomic region
may uncover other potential functional variants that
explain the association. Elucidating the biological path-
ways through which TMEM106B is able to affect disease
risk of FTLD, whether or not by influencing GRN protein
levels, will shed new light on the pathogenic cascade of
FTLD-TDP and FTLD in general. These novel insights
will bring us one step closer in understanding this
devastating dementia disorder and in developing targeted
therapeutic strategies.
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